Neurofeedback from the SMA for Tourette Syndrome

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Yale University School of Medicine, New Haven, CTTourette SyndromeNeurofeedback from the SMA - Other
Eligibility
10 - 16
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether neurofeedback from the supplementary motor area can help reduce tics in adolescents with Tourette Syndrome.

Eligible Conditions
  • Tourette Syndrome

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Baseline and one month post-NF

Baseline and during NF
Change in control over activity in the SMA target region during NF compared to baseline
Baseline and one month post-NF
Changes in resting state functional connectivity to SMA in NF group
Month 1
Change in symptoms after the intervention compared to baseline

Trial Safety

Trial Design

2 Treatment Groups

Neurofeedback from control region
1 of 2
Neurofeedback from the SMA
1 of 2

Active Control

Experimental Treatment

64 Total Participants · 2 Treatment Groups

Primary Treatment: Neurofeedback from the SMA · No Placebo Group · N/A

Neurofeedback from the SMA
Other
Experimental Group · 1 Intervention: Neurofeedback from the SMA · Intervention Types: Other
Neurofeedback from control region
Other
ActiveComparator Group · 1 Intervention: Neurofeedback from control region · Intervention Types: Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline and one month post-nf

Who is running the clinical trial?

National Institute of Mental Health (NIMH)NIH
2,584 Previous Clinical Trials
1,984,748 Total Patients Enrolled
13 Trials studying Tourette Syndrome
3,276 Patients Enrolled for Tourette Syndrome
Yale UniversityLead Sponsor
1,703 Previous Clinical Trials
20,475,865 Total Patients Enrolled
12 Trials studying Tourette Syndrome
539 Patients Enrolled for Tourette Syndrome
Michelle Hampson, PhDPrincipal InvestigatorYale University
3 Previous Clinical Trials
116 Total Patients Enrolled

Eligibility Criteria

Age 10 - 16 · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Participants must be between 10 and 16 years old, regardless of gender.

Frequently Asked Questions

What is the participant count of this clinical experiment?

"Affirmative. Clinicaltrials.gov corroborates that this clinical trial is currently attempting to find 64 participants from 1 medical site. This research was posted on November 1st 2022 with the last update occurring on November 21st 2022." - Anonymous Online Contributor

Unverified Answer

Is the cutoff age for enrolment in this research endeavour higher than 85 years old?

"The requirements for participation in this experiment indicates that the age of participants must be between 10 and 16 years old. Furthermore, there are 382 clinical trials designed specifically for youngsters under 18, as well as 990 for senior citizens over 65." - Anonymous Online Contributor

Unverified Answer

Are any volunteers being sought for this trial at this time?

"Indeed, clinicaltrials.gov reveals that this medical trial is still recruiting participants since its inception on November 1st 2022. The investigation has been updated recently and requires 64 patients to be enrolled across one site." - Anonymous Online Contributor

Unverified Answer

Could I potentially qualify to join this medical experiment?

"This study seeks a total of 64 patients suffering from Gilles de la Tourette Syndrome aged between 10 and 16." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.